Zepbound, Mounjaro and liraglutide are part of the class of weight loss medications called GLP-1s, which have exploded in popularity in recent years. Hims & Hers launched a weight loss program in late 2023, but its GLP-1 offerings have evolved as the company has contended with a volatile supply and regulatory environment.

India took a much-needed step in the fight against obesity and diabetes with the introduction of Mounjaro (tirzepatide), a drug developed by American pharmaceutical giant Eli Lilly and Co. Approved by the Central Drugs Standard Control Organisation (CDSCO),

Eli Lilly launches Mounjaro, the much-awaited diabetes drug, in India. It is priced at ₹3,500 for 2.5 mg. Mounjaro and Ozempic, another popular obesity drug, differ in active ingredients. Let’s take a look at how both drugs tackle type 2 diabetes.

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk for a much-awaited entry into the world's most populous country grappling with increasing rates of obesity and diabetes.

Through his X handler, Kamath revealed that he has been following the developments around Ozempic and GLP-1 drugs with some interest for a while, and last week Eli Lilly launched its variant, Mounjaro,